Table 1.
How do you describe an IF in a clinical context in your CMG, apart from following guidelines? What terminology do you use? | |
What differences do you see between IFs in array testing and in clinical ES? | |
What kind of IFs do you report, firstly from the laboratory to the clinician, and secondly from the clinician to the patient? | |
What kind of policy regarding IFs would you like to create in the future? | |
What impact do international guidelines on reporting IFs have on your own practice? | |
What difficulties do you experience in your practice regarding IFs or SFs? What are the great challenges in the evolution of IFs? | |
What is your current practice regarding a patient’s request to opt out of IFs? | |
How do you consider the intentional search for SFs? | |
What is your practice when new information is available about an IF, for example for recontacting patients? |
Abbreviations used: CMG Centre for medical genetics, IF(s) Incidental finding(s), SF(s) Secondary finding(s), ES Exome sequencing.